Point Break Capital Management LLC Acquires New Stake in Eli Lilly and Company (NYSE:LLY)

Point Break Capital Management LLC acquired a new stake in Eli Lilly and Company (NYSE:LLYFree Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 1,365 shares of the company’s stock, valued at approximately $796,000. Eli Lilly and Company comprises about 0.6% of Point Break Capital Management LLC’s holdings, making the stock its 7th largest position.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $26,000. Tidemark LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $29,000. Optiver Holding B.V. acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth $36,000. St. Johns Investment Management Company LLC raised its stake in shares of Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after buying an additional 37 shares during the last quarter. Finally, O Brien Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 70.5% during the 4th quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock worth $44,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 1.7 %

Shares of Eli Lilly and Company stock traded up $14.61 on Friday, hitting $851.90. 542,772 shares of the company’s stock traded hands, compared to its average volume of 2,934,681. The stock has a market cap of $809.65 billion, a P/E ratio of 125.41, a PEG ratio of 1.81 and a beta of 0.36. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The firm’s 50-day moving average is $774.36 and its 200 day moving average is $706.18. Eli Lilly and Company has a 52-week low of $432.34 and a 52-week high of $856.81.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business’s revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.62 EPS. Equities analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.61%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the sale, the insider now directly owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $809.21, for a total value of $74,902,905.23. Following the completion of the transaction, the insider now owns 98,556,247 shares of the company’s stock, valued at $79,752,700,634.87. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold 337,804 shares of company stock valued at $278,236,284 over the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on LLY shares. The Goldman Sachs Group lifted their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Truist Financial upped their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $769.53.

Check Out Our Latest Report on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.